Opinion on the definition of "occult hepatitis B virus infection"

Rongrong XUE; Xinru WANG; Li XIAO; Chengyuan LIU; Wei WANG; Hongtao XU; Jianchun XIAN

doi:10.3969/j.issn.1001-5256.2023.05.006

Volume 39 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(5): 1037-1040

PDF( 1843 KB)

Opinion on the definition of "occult hepatitis B virus infection"

DOI: 10.3969/j.issn.1001-5256.2023.05.006

1.
Department of Infectious Diseases, the First People's Hospital of Yancheng, Yancheng, Jiangsu 224005, China
2.
Department of Infectious Diseases and Hepatology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China

Research funding:

Taizhou Science and Technology Support Program (Social Development) Project (TS201813)

More Information

Corresponding author: XIAN Jianchun, xianjc09@163.com(ORCID: 0000-0003-0159-2784)
Received Date: 2022-11-16
Accepted Date: 2023-01-05
Published Date: 2023-05-20

Abstract

Abstract

The presence of replication-competent HBV DNA in the liver and/or serum of HBsAg-negative individuals is a sufficient and necessary condition for the diagnosis of occult hepatitis B virus infection (OBI). In recent years, Chinese scholars have proposed what is considered a more "rigorous" definition, i.e., on this basis, HBV window period (WP) infection is excluded, which corresponds to a serum HBV DNA level of below the lower limit of detection or a low positive value (< 200 IU/mL). As the definition of WP for HBV infection remains unclear and its duration is highly variable, "HBV DNA < 200 IU/mL" is not the only criterion in OBI patients. Therefore, it is believed that there is still a lack of sufficient basis and operability for the definition of OBI based on "the exclusion of HBV WP infection" and "HBV DNA < 200 IU/mL" as "rigorous" conditions for the diagnosis of OBI.
- Hepatitis B virus,
- Hepatitis B,
- Viral Load

FullText(HTML)

References(21)

References

[1]	WANDS JR, CHURA CM, ROLL FJ, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders[J]. Gastroenterology, 1975, 68(1): 105-112. DOI: 10.1007/BF02604283.
[2]	HOOFNAGLE JH, SEEFF LB, BALES ZB, et al. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen[J]. N Engl J Med, 1978, 298(25): 1379-1383. DOI: 10.1056/NEJM197806222982502.
[3]	SAITTA C, POLLICINO T, RAIMONDO G. Occult hepatitis B virus infection: An update[J]. Viruses, 2022, 14(7): 1504. DOI: 10.3390/v14071504.
[4]	RAIMONDO G, ALLAIN JP, BRUNETTO MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection[J]. J Hepatol, 2008, 49(4): 652-657. DOI: 10.1016/j.jhep.2008.07.014.
[5]	RAIMONDO G, LOCARNINI S, POLLICINO T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection[J]. J Hepatol, 2019, 71(2): 397-408. DOI: 10.1016/j.jhep.2019.03.034.
[6]	LU FM, WANG J, CHEN XM, et al. Application of the new serum markers in the research and development of innovative hepatitis B drugs[J]. Chin J Hepatol, 2020, 28(8): 649-653. DOI: 10.3760/cma.j.cn501113-20200722-00410. 鲁凤民, 王杰, 陈香梅, 等. 新型血清指标在乙型肝炎创新药物研发中的应用[J]. 中华肝脏病杂志, 2020, 28(8): 649-653. DOI: 10.3760/cma.j.cn501113-20200722-00410-1.
[7]	WANG J, YU GX, LU FM. Clinical application and significance of highly sensitive HBV DNA detection[J]. J Mol Diagn Ther, 2019, 11(5): 343-347, 373. DOI: 10.3969/j.issn.1674-6929.2019.05.002. 王杰, 于广鑫, 鲁凤民. 高灵敏度HBV DNA检测的临床应用及意义[J]. 分子诊断与治疗杂志, 2019, 11(5): 343-347, 373. DOI: 10.3969/j.issn.1674-6929.2019.05.002.
[8]	ZOU J, WANG J, WANG LN, et al. Research progress on occult hepatitis B virus infection and related blood transfusion safety issues[J]. Chin J Infect Dis, 2020, 38(6): 385-388. DOI: 10.3760/cma.j.cn311365-20191016-00335. 邹军, 王杰, 王露楠, 等. 隐匿性乙型肝炎病毒感染及相关输血安全问题的研究进展[J]. 中华传染病杂志, 2020, 38(6): 385-388. DOI: 10.3760/cma.j.cn311365-20191016-00335.
[9]	LU FM, LIAO H, LIU YZ, et al. Re-recognition of occult hepatitis B virus infection[J]. Chin J Prev Med, 2019, 53(5): 445-449. DOI: 10.3760/cma.j.issn.0253-9624.2019.05.002. 鲁凤民, 廖昊, 刘永振, 等. 隐匿性乙型肝炎病毒感染再认识[J]. 中华预防医学杂志, 2019, 53(5): 445-449. DOI: 10.3760/cma.j.issn.0253-9624.2019.05.002.
[10]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[11]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[12]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[13]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[14]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[15]	World Health Organization. WHO guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2015.
[16]	WU D, WANG X, FENG F, et al. Characteristic of HBV nucleic acid amplification testing yields from blood donors in China[J]. BMC Infect Dis, 2021, 21(1): 714. DOI: 10.1186/s12879-021-06468-y.
[17]	SOLDAN K, RAMSAY M, COLLINS M. Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database[J]. BMJ, 1999, 318(7176): 95. DOI: 10.1136/bmj.318.7176.95.
[18]	MIMMS LT, MOSLEY JW, HOLLINGER FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection[J]. BMJ, 1993, 307(6912): 1095-1097. DOI: 10.1136/bmj.307.6912.1095.
[19]	KLEINMAN SH, BUSCH MP. Assessing the impact of HBV NAT on window period reduction and residual risk[J]. J Clin Virol, 2006, 36(Suppl 1): S23-29. DOI: 10.1016/s1386-6532(06)80005-3.
[20]	TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. DOI: 10.1002/hep.28156.
[21]	IM YR, JAGDISH R, LEITH D, et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(10): 932-942. DOI: 10.1016/S2468-1253(22)00201-1.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (622) PDF downloads(138)

Opinion on the definition of "occult hepatitis B virus infection"

DOI: 10.3969/j.issn.1001-5256.2023.05.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Opinion on the definition of "occult hepatitis B virus infection"

DOI: 10.3969/j.issn.1001-5256.2023.05.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content